Cargando…
MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico
Background. Type 1 Diabetes (T1D) is the most common chronic endocrinological disease diagnosed during childhood. It requires continuous education, monitoring and treatment. An analysis was developed to learn if there were discrepancies in the level of metabolic control and complications between pri...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208820/ http://dx.doi.org/10.1210/jendso/bvaa046.2248 |
_version_ | 1783530935740792832 |
---|---|
author | Faradji, Raquel N Garcia Tuomola, Aili L Antonio Villa, Neftali E Velazquez, Maricela Vidrio De la Garza, Natalia E Capetillo, Mayra Valadez Bustamante Martinez, Jorge F Galvez, Guillermo Gonzalez Ortega, Laura Islas Sanchez Ruiz, Karla L Galindo, Carmen Castillo Polanco Preza, Miguel A Yepez Rodriguez, Alicia E Mendez, Angelica Martinez Ramos Ortiz, Ana Rosa Escobedo Valenzuela, Julio Cesar Hermosillo, Aldo Ferreira Zazueta, Alejandro Romero Lopez, Sigfrido Miracle Valdes, Paloma Almeda |
author_facet | Faradji, Raquel N Garcia Tuomola, Aili L Antonio Villa, Neftali E Velazquez, Maricela Vidrio De la Garza, Natalia E Capetillo, Mayra Valadez Bustamante Martinez, Jorge F Galvez, Guillermo Gonzalez Ortega, Laura Islas Sanchez Ruiz, Karla L Galindo, Carmen Castillo Polanco Preza, Miguel A Yepez Rodriguez, Alicia E Mendez, Angelica Martinez Ramos Ortiz, Ana Rosa Escobedo Valenzuela, Julio Cesar Hermosillo, Aldo Ferreira Zazueta, Alejandro Romero Lopez, Sigfrido Miracle Valdes, Paloma Almeda |
author_sort | Faradji, Raquel N |
collection | PubMed |
description | Background. Type 1 Diabetes (T1D) is the most common chronic endocrinological disease diagnosed during childhood. It requires continuous education, monitoring and treatment. An analysis was developed to learn if there were discrepancies in the level of metabolic control and complications between private and public healthcare in Mexico, based on the data obtained in the National Registry of patients with Type 1 Diabetes (RENACED DT1). Objective: Describe the sociodemographic characteristics, metabolic control, treatment and complications in patients receiving private or public health care registered in RENACED DT1.Methodology: Sociodemographic and anthropometric variables, metabolic control, diabetes education, type of insulin and delivery method used for treatment, glucose monitoring and acute and chronic complications were compared between patients receiving private vs public health care. Results Of the 1458 patients registered, significant differences between HbA1c levels were seen (7.8% private health care vs 8.7% public healthcare, p<0.001), achievement of glycemic goal HbA1c <7% (30.1% private healthcare vs 19.6% public healthcare, p<0.001). In private institutions, 47.1% of patients use an insulin pump and 44.7% a basal bolus regimen with insulin analogues (MDI) (p<0.001). Meanwhile in public institutions, 2.6% use an insulin pump and 84.8% use MDI (p<0.001). 30.4% of patients in private institutions check their blood glucose levels 6 to 10 times a day vs 14.3% of patients from public institutions (p<0.001). Continuous glucose monitoring is used in 46.4% of patients from private healthcare vs 5% from public healthcare (p<0.001). A larger number of patients from private healthcare use insulin to carbohydrate ratios to calculate meal insulin compared with patients from public healthcare (89.1% vs 31.3%, p<0.001). No significant differences were found related to the incidence of mild to moderate hypoglycemia, but there was a higher incidence of severe hypoglycemia in the public sector compared to the private one (57 vs 43%, p<0.001). Also, a higher prevalence of diabetic nephropathy was found in patients from public vs private healthcare (82.9 vs 17.1%, p=0.034). Conclusions: Significant differences were found in glucose monitoring, carbohydrate counting and insulin delivery methods, between patients from public and private healthcare, which could explain the differences observed in metabolic control and diabetes associated complications. It is imperative that better public policies are implemented in public health, to reduce this health disparity. |
format | Online Article Text |
id | pubmed-7208820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72088202020-05-13 MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico Faradji, Raquel N Garcia Tuomola, Aili L Antonio Villa, Neftali E Velazquez, Maricela Vidrio De la Garza, Natalia E Capetillo, Mayra Valadez Bustamante Martinez, Jorge F Galvez, Guillermo Gonzalez Ortega, Laura Islas Sanchez Ruiz, Karla L Galindo, Carmen Castillo Polanco Preza, Miguel A Yepez Rodriguez, Alicia E Mendez, Angelica Martinez Ramos Ortiz, Ana Rosa Escobedo Valenzuela, Julio Cesar Hermosillo, Aldo Ferreira Zazueta, Alejandro Romero Lopez, Sigfrido Miracle Valdes, Paloma Almeda J Endocr Soc Diabetes Mellitus and Glucose Metabolism Background. Type 1 Diabetes (T1D) is the most common chronic endocrinological disease diagnosed during childhood. It requires continuous education, monitoring and treatment. An analysis was developed to learn if there were discrepancies in the level of metabolic control and complications between private and public healthcare in Mexico, based on the data obtained in the National Registry of patients with Type 1 Diabetes (RENACED DT1). Objective: Describe the sociodemographic characteristics, metabolic control, treatment and complications in patients receiving private or public health care registered in RENACED DT1.Methodology: Sociodemographic and anthropometric variables, metabolic control, diabetes education, type of insulin and delivery method used for treatment, glucose monitoring and acute and chronic complications were compared between patients receiving private vs public health care. Results Of the 1458 patients registered, significant differences between HbA1c levels were seen (7.8% private health care vs 8.7% public healthcare, p<0.001), achievement of glycemic goal HbA1c <7% (30.1% private healthcare vs 19.6% public healthcare, p<0.001). In private institutions, 47.1% of patients use an insulin pump and 44.7% a basal bolus regimen with insulin analogues (MDI) (p<0.001). Meanwhile in public institutions, 2.6% use an insulin pump and 84.8% use MDI (p<0.001). 30.4% of patients in private institutions check their blood glucose levels 6 to 10 times a day vs 14.3% of patients from public institutions (p<0.001). Continuous glucose monitoring is used in 46.4% of patients from private healthcare vs 5% from public healthcare (p<0.001). A larger number of patients from private healthcare use insulin to carbohydrate ratios to calculate meal insulin compared with patients from public healthcare (89.1% vs 31.3%, p<0.001). No significant differences were found related to the incidence of mild to moderate hypoglycemia, but there was a higher incidence of severe hypoglycemia in the public sector compared to the private one (57 vs 43%, p<0.001). Also, a higher prevalence of diabetic nephropathy was found in patients from public vs private healthcare (82.9 vs 17.1%, p=0.034). Conclusions: Significant differences were found in glucose monitoring, carbohydrate counting and insulin delivery methods, between patients from public and private healthcare, which could explain the differences observed in metabolic control and diabetes associated complications. It is imperative that better public policies are implemented in public health, to reduce this health disparity. Oxford University Press 2020-05-08 /pmc/articles/PMC7208820/ http://dx.doi.org/10.1210/jendso/bvaa046.2248 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Diabetes Mellitus and Glucose Metabolism Faradji, Raquel N Garcia Tuomola, Aili L Antonio Villa, Neftali E Velazquez, Maricela Vidrio De la Garza, Natalia E Capetillo, Mayra Valadez Bustamante Martinez, Jorge F Galvez, Guillermo Gonzalez Ortega, Laura Islas Sanchez Ruiz, Karla L Galindo, Carmen Castillo Polanco Preza, Miguel A Yepez Rodriguez, Alicia E Mendez, Angelica Martinez Ramos Ortiz, Ana Rosa Escobedo Valenzuela, Julio Cesar Hermosillo, Aldo Ferreira Zazueta, Alejandro Romero Lopez, Sigfrido Miracle Valdes, Paloma Almeda MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico |
title | MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico |
title_full | MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico |
title_fullStr | MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico |
title_full_unstemmed | MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico |
title_short | MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico |
title_sort | mon-lb117 differences in metabolic control, treatment and associated complications in patients living with type 1 diabetes receiving private or public health care in mexico |
topic | Diabetes Mellitus and Glucose Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208820/ http://dx.doi.org/10.1210/jendso/bvaa046.2248 |
work_keys_str_mv | AT faradjiraqueln monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT garciatuomolaailil monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT antoniovillaneftalie monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT velazquezmaricelavidrio monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT delagarzanataliae monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT capetillomayravaladez monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT bustamantemartinezjorgef monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT galvezguillermogonzalez monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT ortegalauraislas monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT sanchezruizkarlal monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT galindocarmencastillo monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT polancoprezamiguela monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT yepezrodriguezaliciae monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT mendezangelicamartinezramos monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT ortizanarosaescobedo monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT valenzuelajuliocesar monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT hermosilloaldoferreira monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT zazuetaalejandroromero monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT lopezsigfridomiracle monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico AT valdespalomaalmeda monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico |